331 related articles for article (PubMed ID: 25031337)
1. P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.
Swartz TH; Esposito AM; Durham ND; Hartmann BM; Chen BK
J Virol; 2014 Oct; 88(19):11504-15. PubMed ID: 25031337
[TBL] [Abstract][Full Text] [Related]
2. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
[TBL] [Abstract][Full Text] [Related]
3. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
4. Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection.
Lee DY; Lin X; Paskaleva EE; Liu Y; Puttamadappa SS; Thornber C; Drake JR; Habulin M; Shekhtman A; Canki M
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1231-41. PubMed ID: 20001317
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput HIV-Cell Fusion Assay for Discovery of Virus Entry Inhibitors.
Marin M; Du Y; Giroud C; Kim JH; Qui M; Fu H; Melikyan GB
Assay Drug Dev Technol; 2015 Apr; 13(3):155-66. PubMed ID: 25871547
[TBL] [Abstract][Full Text] [Related]
6. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
7. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
8. In vitro replicative fitness of early Transmitted founder HIV-1 variants and sensitivity to Interferon alpha.
Ashokkumar M; Sonawane A; Sperk M; Tripathy SP; Neogi U; Hanna LE
Sci Rep; 2020 Feb; 10(1):2747. PubMed ID: 32066770
[TBL] [Abstract][Full Text] [Related]
9. Distinct efficacy of HIV-1 entry inhibitors to prevent cell-to-cell transfer of R5 and X4 viruses across a human placental trophoblast barrier in a reconstitution model in vitro.
Ayouba A; Cannou C; Nugeyre MT; Barré-Sinoussi F; Menu E
Retrovirology; 2008 Mar; 5():31. PubMed ID: 18377645
[TBL] [Abstract][Full Text] [Related]
10. Purinergic Receptors: Elucidating the Role of these Immune Mediators in HIV-1 Fusion.
Freeman TL; Swartz TH
Viruses; 2020 Mar; 12(3):. PubMed ID: 32155980
[TBL] [Abstract][Full Text] [Related]
11. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1.
Kopetzki E; Jekle A; Ji C; Rao E; Zhang J; Fischer S; Cammack N; Sankuratri S; Heilek G
Virol J; 2008 May; 5():56. PubMed ID: 18452606
[TBL] [Abstract][Full Text] [Related]
12. An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.
Bozek K; Eckhardt M; Sierra S; Anders M; Kaiser R; Kräusslich HG; Müller B; Lengauer T
Retrovirology; 2012 Jul; 9():60. PubMed ID: 22830600
[TBL] [Abstract][Full Text] [Related]
13. Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
Harmon B; Campbell N; Ratner L
PLoS Pathog; 2010 Jun; 6(6):e1000956. PubMed ID: 20585556
[TBL] [Abstract][Full Text] [Related]
14. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV-1 infection by human α-defensin-5, a natural antimicrobial peptide expressed in the genital and intestinal mucosae.
Furci L; Tolazzi M; Sironi F; Vassena L; Lusso P
PLoS One; 2012; 7(9):e45208. PubMed ID: 23028850
[TBL] [Abstract][Full Text] [Related]
16. P2X1 Selective Antagonists Block HIV-1 Infection through Inhibition of Envelope Conformation-Dependent Fusion.
Soare AY; Malik HS; Durham ND; Freeman TL; Alvarez R; Patel F; Satija N; Upadhyay C; Hioe CE; Chen BK; Swartz TH
J Virol; 2020 Feb; 94(6):. PubMed ID: 31852781
[TBL] [Abstract][Full Text] [Related]
17. [Viral entry as therapeutic target. Current situation of entry inhibitors].
Arenzana-Seisdedos F
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215
[TBL] [Abstract][Full Text] [Related]
18. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
19. P2X Antagonists Inhibit HIV-1 Productive Infection and Inflammatory Cytokines Interleukin-10 (IL-10) and IL-1β in a Human Tonsil Explant Model.
Soare AY; Durham ND; Gopal R; Tweel B; Hoffman KW; Brown JA; O'Brien M; Bhardwaj N; Lim JK; Chen BK; Swartz TH
J Virol; 2019 Jan; 93(1):. PubMed ID: 30305360
[TBL] [Abstract][Full Text] [Related]
20. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
